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Abstract
Background: The standard electrode array for the MED-EL MAESTRO cochlear implant system
is 31 mm in length which allows an insertion angle of approximately 720°. When fully inserted, this
long electrode array is capable of stimulating the most apical region of the cochlea. No investigation
has explored Electrically Evoked Compound Action Potential (ECAP) recordings in this region with
a large number of subjects using a commercially available cochlear implant system. The aim of this
study is to determine if certain properties of ECAP recordings vary, depending on the stimulation
site in the cochlea.
Methods: Recordings of auditory nerve responses were conducted in 67 subjects to demonstrate
the feasibility of ECAP recordings using the Auditory Nerve Response Telemetry (ART™) feature
of the MED-EL MAESTRO system software. These recordings were then analyzed based on the
site of cochlear stimulation defined as basal, middle and apical to determine if the amplitude,
threshold and slope of the amplitude growth function and the refractory time differs depending on
the region of stimulation.
Results: Findings show significant differences in the ECAP recordings depending on the stimulation
site. Comparing the apical with the basal region, on average higher amplitudes, lower thresholds
and steeper slopes of the amplitude growth function have been observed. The refractory time
shows an overall dependence on cochlear region; however post-hoc tests showed no significant
effect between individual regions.
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Conclusions: Obtaining ECAP recordings is also possible in the most apical region of the cochlea.
However, differences can be observed depending on the region of the cochlea stimulated.
Specifically, significant higher ECAP amplitude, lower thresholds and steeper amplitude growth
function slopes have been observed in the apical region. These differences could be explained by
the location of the stimulating electrode with respect to the neural tissue in the cochlea, a higher
density, or an increased neural survival rate of neural tissue in the apex.
Trial registration: The Clinical Investigation has the Competent Authority registration number
DE/CA126/AP4/3332/18/05.
Background
Objective measures are a widely used and valuable tool in
the field of cochlear implants (CIs). During surgery they
provide first indications of successful implantation and
after surgery they are used to facilitate the individual fit-
ting of stimulation parameters. One objective measure of
the auditory nerve's response to stimulation is the Electri-
cally Evoked Compound Action Potential (ECAP). This
response is particularly advantageous because it allows
the clinician to directly measure auditory nerve fibre
potentials on implanted patients. In analyzing the physi-
ological response to the electrical stimulation transmitted
by the implant, information can be obtained regarding
the expected and actual function of the peripheral nerve.
This information can be used intraoperatively to adjust
the placement of the intracochlear electrode and for tech-
nical functional testing. Postoperatively, the ECAP record-
ings can be used to measure the neuronal potentials
elicited by electrode stimulation along the basilar mem-
brane. In addition, these measurements may help to
determine the upper and lower limits of the stimulation
current [the hearing threshold (THR) and the maximum
comfort level (MCL)] in cases of fitting [1-7] or to evaluate
the stimulation current field along the cochlea and the
interaction of individual electrodes [8-10].
Stimulation of an intracochlear electrode results in the
excitation of specific populations of neural fibres that are
distributed along the basilar membrane. Previous investi-
gations have been limited in terms of how much of the
cochlea can be analyzed because of maximal insertion
depths and insertion angles of the electrode arrays. For
this investigation, the Auditory Nerve Telemetry (ART)
[11] in the MED-EL MAESTRO CI system (MED-EL, Inns-
bruck, Austria) was used to perform ECAP recordings. The
MED-EL standard electrode array allows an insertion
depth of 31 mm or 720° and comprises 12 channels [12],
allowing access to the most apical region of the cochlea.
The channels are spaced 2.4 mm apart, and are numbered
E 1 to E 12, from apical to basal.
The primary objective of this study was to establish
whether a difference exists in ECAP properties depending
on the region of the cochlea that is stimulated and meas-
ured. Previous studies using other CI systems found
increased ECAP amplitudes at the apical electrodes
[13,14]. Note that these publications did not realize a full
cochlear coverage. Also electrophysiological models did
not analyze a (deep) apical stimulation, comparing it with
a middle or basal stimulation. Therefore in this study, an
analysis of amplitude, threshold, and slope of the ECAP
recordings obtained in various regions of cochlear stimu-
lation was conducted. A secondary objective of this study
was to determine if the ECAP amplitude in relative refrac-
tory state shows systematic differences for different stimu-
lation and recording sites.
Methods
Subjects
46 experienced and 21 inexperienced CI users were
recruited from 13 centres in Germany for a clinical study
[15,16] investigating CI coding strategies and ECAP
recordings. The study was approved by the International
Freiburger Ethic Commission (FECI 05/2134). Of these
67 CI subjects, 34 were women and 33 were men. The
mean age at onset of hearing loss was 43.4 years with a
range of 1 to 73 years. The mean age at implantation was
55.4 years with a range of 20 to 76 years. 37 subjects were
implanted on the left side and 30 were implanted on the
right. All subjects were postlingually deaf, (defined as an
onset of severe-to-profound sensorineural hearing loss
occurring after 6 years of age) and were unilaterally
implanted with a MED-EL PULSARci100 or SONATAti100
using the standard electrode array. All subjects were
required to have at least 10 active electrodes at the last fit-
ting. All subjects were native German speakers.
Subject groups
Experienced subjects were adults (18 years or older) with
a minimum of six months of device experience (mean =
1.4 years; range = 7 to 31 months). The inexperienced sub-
jects were adults who received their first CI after having
undergone a hearing aid trial where minimal aided bene-
fit from hearing aid(s) was determined. These subjects fell
within the medical and audiological guidelines estab-
lished by their respective centres for cochlear implanta-BioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
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tion. Apart from experience with the device, the inclusion
criteria were the same for both the experienced and inex-
perienced groups.
Statistical Analysis
If for one subject more than one recording of an ECAP
property was available, the mean value was used in the
analysis. To test the hypotheses, a general linear model
was applied and analyses of variance (ANOVA) for
repeated measurements [17] with the region as factor were
performed for each test condition. If the assumption of
sphericity was not tenable according to Mauchly's test
[18], the Greenhouse-Geisser correction [19] was applied.
To detect significant effects of the region on the ECAP
measurement, parametric paired Student's t-tests were
used. After adjustments for multiple comparisons with
the use of Bonferroni's procedure [20] p-values of less
than 0.017 were considered to indicate statistical signifi-
cance. The software employed for the statistical analysis
was Matlab Rev 7.0.0.19920 with the Statistics Toolbox
Version 5.0.
ECAP Measurements
ECAP measurements were performed as part of a study
[15,16] evaluating ECAP recordings, and the performance
of subjects with the Fine Structure Processing (FSP) strat-
egy as improved in the OPUS audio processors, acutely
and after three months of device use. ECAPs were
recorded postoperatively using the MAESTRO 2.0 system
software connected to a DIB II interface box. For the expe-
rienced subjects ECAP recordings were obtained at acute
switch-over from their clinical TEMPO+ speech processor
to the OPUS 1 speech processor employing the FSP coding
strategy, and for the inexperienced subjects at initial stim-
ulation. If no ECAP could be recorded from a subject of
either group, measurements were reattempted three
months after the initial test date.
ECAP amplitude, threshold and slope were measured
using amplitude growth sequences. These recording
sequences consisted of several single recordings that had
one stimulation pulse followed by an ECAP measure-
ment. The single recordings were separated by approxi-
mately 30 ms, assuming a relative refractory time below
10 ms. The phase duration was set to 30 μs and the stim-
ulation amplitude was defined in current unit (cu), where
1 cu corresponds to approximately 1 μA. Across the
sequence, the stimulation amplitude for a single record-
ing was raised from 0 cu to a maximum value, which typ-
ically correlates to the patient's MCL, for example, 640 cu.
Additionally, in the experienced users, recovery sequence
results were measured. Recovery sequences consisted of
independent single recordings that had two stimulation
pulses followed by an ECAP measurement. The time
between the onset of the two pulses (inter-pulse interval
or IPI) was 300, 400, 500, 750, 1000, 1500, 2000, 2500,
3000, 5000, 6000 and 8000 μs. The recovery inter-pulse
interval (rIPI) was defined as that IPI that would result in
an ECAP having an amplitude that is the mean of the max-
imal and the minimal amplitude measured in the recov-
ery sequence (see Figure 1). The fixed sampling of the IPIs
defines the maximal and minimal amplitude, i.e. the rIPI,
independent of any user interpretation and allows for a
relative comparison between the different electrode posi-
tions. An alternative way to reduce the influence of any
measurement noise or residual artifact would be an
extrapolation of the recovery function [21], which was not
possible as the report forms of the analyzed study only
contained the minimal and maximal amplitude and the
rIPI itself.
For all measurements, the stimulation artifact was
removed using an alternating stimulation approach. Each
measurement is performed twice, with a cathodic/anodic
and an anodic/cathodic stimulation pulse, respectively.
When averaging the two measurements, the stimulation
artifact vanishes and the ECAP signal remains. The record-
ing artifact was removed subtracting a zero amplitude
template [2].
Electrode Regions
The stimulation region was subdivided into three regions
according to the electrode and its approximate location
within the cochlea (see Table 1). In subjects with 12 active
electrodes, the basal region was defined as Electrodes 9 to
12, the middle region included Electrodes 5 to 8 and the
apical region included Electrodes 1 to 4. If the most basal
electrode (Electrode 12) was deactivated, it was assumed
that the electrode array was not fully inserted and the
mapping was shifted by one electrode, resulting in the api-
cal region containing Electrodes 1 to 3 (instead of Elec-
trodes 1 to 4). Likewise, if Electrodes 11 and 12 were not
activated, the ranges shifted by two electrodes so that the
apical region included Electrodes 1 and 2 only. If any
other electrodes were not activated, no shifts were applied
and the deactivated electrode was excluded from the data
analysis. Of the 67 subjects, all 12 electrodes were acti-
vated in 48 users (71.6%). 11 electrodes were activated in
14 users (20.9%) and for 5 users (7.5%), 10 electrodes
were activated.
Results
The ECAP results reported below are summarized in Table
2. Results from the statistical tests are summarized in
Table 3. The data collected was subsequently analyzed for
the purpose of determining if differences existed in ECAP
recordings obtained in various regions of the cochlea. In
this analysis, the experienced and inexperienced group
were merged into one group (N = 67) in order to gain a
more consolidated analysis of possible effects dependingBioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
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of the stimulation site. To rule out any effects of a signifi-
cant difference between the experienced and inexperi-
enced groups, we performed t-tests for amplitude,
threshold and slope. The results revealed no significant
differences between the two groups.
Ecap Amplitude Growth Sequence
ECAP measurements were possible for 58 users account-
ing for 86.6% of all subjects. Within our subjects, the pres-
ence or absence of ECAP recordings varied between ECAP
recordings sites. The presence of a clear response was
greatest when the stimulating electrode and measuring
electrode were in the middle and apical region of the
cochlea. Recordings from the middle region were
obtained in 52 (77.6%) subjects, and from the apical
region in 51 (76.1%). In the basal region, responses were
obtained in 38 subjects (56.7%). The small number of
subjects who had responses in the basal region reduced
the number of subjects for whom ECAPs were successfully
measured in all three regions to 34 users (50.7%). Data
reporting is therefore based on those subjects (N = 34)
except where otherwise stated.
Ecap Recovery Sequence
Recovery sequences were measured in the experienced
group (N = 46). Unlike for the amplitude growth
sequence, variability in the presence or absence of a clear
response depending on the cochlear region was not seen.
Clear responses were recorded for 21 subjects (45.7%) in
the basal region, for 25 subjects (54.3%) in the middle
region, and for 21 subjects (45.7%) in the apical region.
There were 16 subjects (34.8%) for whom an ECAP recov-
ery sequence could be measured in all three regions and
29 subjects (63.0%) for whom an ECAP recovery
sequence determination was possible in any region.
Recovery inter-pulse interval (rIPI) Figure 1
Recovery inter-pulse interval (rIPI). To compute the recovery inter-pulse interval (rIPI) the ECAP amplitude is measured 
for a range of different IPIs. The rIPI is defined as the IPI that would result in the mean of the maximal and the minimal ampli-
tude measured.
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Table 1: Mapping of the electrodes to the cochlear region depending on the electrode insertion depth.
E l e c t r o d e 1 2 3456789 1 01 11 2
Active Electrodes: 1-12 a a a a m m m m b b b b
A c t i v e  E l e c t r o d e s :  1 - 1 1 aaa mmmmb bb b -
A c t i v e  E l e c t r o d e s :  1 - 1 0 aammmmb b bb - -
Regions are encoded as: a = apical, m = middle, b = basal.BioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
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Ecap Amplitude Using Amplitude Growth Sequence
ECAP amplitude recordings using an amplitude growth
sequence were compared to maximum ECAP amplitudes
from ECAP recovery sequences. They showed a strong cor-
relation (Pearson's coefficient, r = 0.945) (Figure 2) and a
t-test showed no significant differences between them (p
= 0.116). This confirms the correctness of the ECAP
amplitude measurements in the study.
In Figure 3 ECAP amplitudes measured with an amplitude
growth sequence are shown for the different cochlear
stimulation sites. The mean ECAP amplitude was the low-
est for the basal region (220.8 ± 114.4 μV); compared to
257.9 ± 129.7 μV for the middle and 341.3 ± 200.5 μV for
the apical region. Mauchly's sphericity test, which was
always performed with a Bonferroni corrected significance
level of α = 0.05/3, showed that the assumption of
sphericity is violated. Therefore, a Greenhouse-Geisser
correction of ε = 0.748 was applied to the ANOVA result-
ing in p < 0.001 and F = 10.994. These results show that
there is a significant effect of the stimulation region on the
ECAP amplitude. Paired t-tests revealed that significant
differences on ECAP amplitude exist between the basal
and apical regions (p < 0.001) as well as the middle and
apical regions (p = 0.004), though between the basal and
middle regions no significant effect was found (p = 0.05).
Ecap Threshold Using Amplitude Growth Sequence
In Figure 4 the ECAP thresholds analyzed for all three
regions are shown. The mean ECAP threshold was with
356.2 ± 114.0 cu the highest for the basal region, com-
pared to 337.8 ± 100.2 cu for the middle region, and
307.3 ± 113.7 cu for the apical region. A Greenhouse-
Geisser correction of ε = 0.999 was applied to the ANOVA
as Mauchly's sphericity test showed that the assumption
of sphericity is violated. The ANOVA revealed a significant
effect of stimulation region on the ECAP threshold (p =
0.007 and F = 5.376). Post-hoc testing further showed that
a significant difference in the ECAP threshold exists
between the basal and apical regions (p = 0.003). The
basal and middle regions (p = 0.231) as well as the middle
and apical regions (p = 0.05) did not show significant dif-
ferences.
Slope of Ecap Amplitude Growth Function
The results shown in Figure 5 represent the slope of a lin-
ear fit applied to the rising part of the ECAP amplitude
growth function. This linear fit is by default applied auto-
matically by the MAESTRO clinical software. The smallest
inclination of the mean slope was observed for the basal
region (0.747 ± 0.389 μV/cu), compared to 0.766 ± 0.384
μV/cu for the middle region and 1.092 ± 0.638 μV/cu for
the apical region. Mauchly's sphericity test showed that
the assumption of sphericity is violated for this data set.
Table 2: The ECAP measurement results reported as mean values with the standard deviation.
basal middle apical full region
ECAP amplitude 220.8 ± 114.4 μV 257.9 ± 129.7 μV 341.3 ± 200.5 μV 273.3 ± 159.6 μV
ECAP threshold 356.2 ± 114.0 cu 337.8 ± 100.2 cu 307.3 ± 113.7 cu 333.8 ± 110.3 cu
ECAP amplitude growth function 0.747 ± 0.389 μV/cu 0.766 ± 0.384 μV/cu 1.092 ± 0.638 μV/cu 0.869 ± 0.506 μV/cu
ECAP amplitude recovery sequence 163.3 ± 87.7 μV 192.8 ± 70.2 μV 223.4 ± 104.2 μV 193.2 ± 90.1 μV
ECAP rIPI 1267.9 ± 301.9 μs 1236.0 ± 415.6 μs 1519.0 ± 431.8 μs 1341.0 ± 400.1 μs
Table 3: Observed regional effects on the respective ECAP features.
ANOVA t-test basal-apical t-test middle-apical t-test middle-basal Mauchly's
Test
Greenhouse
Geisser
ECAP amplitude P < 0.001
F = 10.994
p = 0.0007 p = 0.0035 p = 0.0527 No sphericity ε = 0.748
ECAP threshold P = 0.003
F = 5.376
p = 0.0026 p = 0.0511 p = 0.2314 No sphericity ε = 0.999
ECAP slope 
(ampl. growth function)
P < 0.001
F = 12.038
p = 0.0014 p = 0.0002 p = 0.7055 No sphericity ε = 0.690
ECAP amplitude 
(recovery function)
P = 0.045
F = 3.460
p = 0.0086 p = 0.2770 p = 0.1775 sphericity -
ECAP Recovery
Interpulse nterval (rIPI)
P = 0.029
F = 4.015
p = 0.0590 p = 0.0262 p = 0.7198 sphericity -
The results of the statistical analysis are shown. Significant results are printed in boldface. The Bonferroni corrected significance level was α = 
0.0167.BioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
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ECAP amplitude as function of maximal ECAP recovery amplitude Figure 2
ECAP amplitude as function of maximal ECAP recovery amplitude. The maximal amplitude measured with the 
ECAP recovery sequence for the group of experienced users is plotted against the measured ECAP amplitudes. The Pearson's 
correlation coefficient is r = 0.945.
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ECAP amplitudes for the different regions of the cochlea Figure 3
ECAP amplitudes for the different regions of the 
cochlea. ECAP amplitudes measured are shown for the dif-
ferent regions. There are significant differences between the 
basal and apical regions (p < 0.001) as well as the middle and 
apical regions (p = 0.003).
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ECAP thresholds for the different regions Figure 4
ECAP thresholds for the different regions. The meas-
ured ECAP thresholds shown for the different regions. There 
is a significant difference between the basal and apical region 
(p = 0.0026).
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An ANOVA with a Greenhouse-Geisser correction of ε =
0.690 showed a significant effect of the three different
stimulation regions on the ECAP growth function (p <
0.001 and F = 12.038). Post-hoc tests revealed that there
is a significant effect between the basal and apical regions
(p = 0.001) as well as between the middle and apical
regions (p < 0.001). The basal and middle regions showed
no significant difference (p = 0.706).
Ecap Amplitude Derived Using Recovery Sequence
The results shown in Figure 6 represent the ECAP ampli-
tude at the recovery inter-pulse interval (rIPI) as defined
in Figure 1. The ECAP amplitudes presented here thus rep-
resent ECAP amplitudes in relative refractory state. They
were derived using a recovery sequence for 16 experienced
subjects where ECAP recovery sequences were available
for all 3 regions. The mean ECAP amplitude in the basal
region was 163.3 ± 87.7 μV, 192.8 ± 70.2 μV in the middle
region and 223.4 ± 104.2 μV in the apical region.
Mauchly's sphericity test showed that the assumption of
sphericity is tenable. The ANOVA yielded p = 0.045 and F
= 3.460, indicating a significant effect of stimulation
region on ECAP amplitude in relative refractory state.
Post-hoc tests revealed a significant effect between the
basal and apical regions (p = 0.008). No significant effect
was found between the middle and apical regions (p =
0.277) as well as the basal and middle regions (p = 0.178).
Recovery Inter-Pulse Interval (rIPI)
The recovery inter-pulse intervals as defined in Figure 1
are presented in Figure 7. The mean recovery inter-pulse
interval was 1267.9 ± 301.9 μs for the basal region,
1236.0 ± 415.6 μs for the middle region and 1519.0 ±
431.8 μs for the apical region for the 16 experienced sub-
jects where ECAP recovery sequences were available for all
3 regions. Mauchly's sphericity test with a Bonferroni cor-
rected significance level of α = 0.05/3 showed that the
assumption of sphericity is tenable. The ANOVA showed
with p = 0.029 and F = 4.015 that there is a significant
effect of stimulation region on recovery inter-pulse inter-
val. However, post-hoc tests revealed no significant effects
between the basal and apical regions (p = 0.059), middle
ECAP amplitude growth function for the different regions Figure 5
ECAP amplitude growth function for the different 
regions. The slope of the fitted ECAP amplitude growth 
function is shown for the different regions. There are signifi-
cant differences between the basal and apical region (p = 
0.001) as well as the middle and apical region (p < 0.001).
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ECAP amplitude in relative refractory state for the different  regions Figure 6
ECAP amplitude in relative refractory state for the 
different regions. The ECAP amplitude in relative refrac-
tory state shown for the different regions. There is a signifi-
cant difference between the basal and apical region (p = 
0.008).
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Recovery inter-pulse interval (rIPI) for the different regions Figure 7
Recovery inter-pulse interval (rIPI) for the different 
regions. The recovery inter-pulse interval (rIPI, as defined in 
Figure 1) shows an overall dependence on cochlear region, 
however post-hoc tests showed no significant effect between 
individual regions.
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and apical regions (p = 0.026) or the basal and middle
regions (p = 0.719).
Discussion
In this study we examined if certain properties of ECAP
recordings vary, depending on the stimulation site in the
cochlea. To various degrees, we found a significant effect
of stimulation site on ECAP amplitude, ECAP threshold,
slope of ECAP amplitude growth function and ECAP
recovery inter-pulse interval (Table 2, Table 3).
The significant increase in ECAP amplitude towards the
apical region could be explained by a narrowed distance
between the recording electrode and the stimulated neural
tissue (because of reduced diameter of the cochlear turns
towards the apex). Another possible factor is the neural
tissue itself. A greater density or survival rate of neuronal
tissue adjacent to the electrode in the apical region could
also explain the increase in ECAP amplitude which is also
supported by the steeper growth function observable in
Figure 5. Better neural survival of neural structures in the
apex might be produced by later deafening of the apex,
e.g. in many cases of progredient deafness. Differences in
impedances of the electrode-tissue interfaces between
cochlear regions can not explain this effect because the
implant uses current sources and high-impedance record-
ing circuitry and is therefore not affected by different elec-
trode-tissue interface impedances.
We also investigated for the analyzed subjects whether an
increased stimulation amplitude towards the apical
region might be responsible for the amplitude increase.
For the basal region the mean stimulation amplitude was
654.0 ± 224.4 μV. For the middle and apical region, mean
stimulation amplitudes were 723.1 ± 293.8 μV and 706.9
± 317.1 μV, respectively. An ANOVA showed that the
stimulus amplitudes are not dependent of the measure-
ment region (p = 0.244, F = 1.445). As stimulation ampli-
tudes at initial stimulation usually differ from amplitudes
for experienced users, we did also an ANOVA for the expe-
rienced users only, which in contrast to the data above
showed a region dependency of the stimulation ampli-
tudes (p = 0.001, F = 7.730). Paired t-tests show that there
is a significant difference between the basal and middle (p
= 0.001) as well as the basal and apical region (p = 0.004).
This could partially have contributed to the ECAP ampli-
tude increase towards the apex. The middle and apical
region, however, shows no significant difference (p =
0.812) in stimulation amplitude although a significant
difference in ECAP amplitude was found here also (p =
0.004), as mentioned above. Therefore the chosen stimu-
lation amplitude can only partly explain the region
dependency of the ECAP amplitude. This is confirmed by
the fact that studies using other CI systems also found
increased ECAP amplitudes for more apical electrodes
[13,14].
The significant decrease in ECAP threshold towards the
apex could again be attributed to the narrowed distance
between the recording electrode and the surrounding tis-
sue. Additionally, similar to above, a greater density of
neuronal tissue or survival rate adjacent to the electrode
could also lead to a reduction in the stimulation ampli-
tude required to trigger an action potential. As mentioned
previously, regional differences in the impedance of the
electrodes cannot explain the decrease towards the apex.
The slope of the ECAP growth function should strongly
correlate with an increase in the number of neurons that
respond to every increment in stimulation level. The
steeper growth function shown in Figure 5 indicates that
towards the apical region, a greater number of neural ele-
ments are activated for every increment in stimulation
level. Since spiral ganglion cells do not extend into the
apical region of the cochlea, these neural elements should
mainly be afferent peripheral axons.
As the ECAP amplitudes from the recovery sequences did
not differ significantly from those from growth sequences,
ECAP amplitudes from recovery sequences also showed a
region dependency effect. The significant difference in
ECAP amplitudes between the basal and apical region is
also found here. The fact that - in contrast to ECAP ampli-
tudes from growth sequences - no significant difference
between the middle and apical region could be found
here is presumably due to the smaller subject group (16
instead of 34) in which recovery sequences were per-
formed.
The recovery interpulse interval (rIPI) shows an overall
effect but no significant post-hoc differences for different
stimulation and recording sites. There are at least two dif-
ferent mechanisms that could lead to changes in the
latency of ECAP potentials along the cochlea: Some firing
features of type II spiral ganglion neurons are cochlear
region dependent; the latency is reported to be longer for
the apical region [22,23] (determined in murine cochlea).
Secondly, the latency depends on the site of stimulation
and recording sites. These locations depend on the spiral
ganglion cell arrangement between apex and base that is
reported to be different [24,25] (human cochlea). This
effect is also assumed to be the reason for the double P
peaks, seen in 9.5% of ECAP responses [26].
The observed increase in ECAP amplitude towards the
apex of the cochlea adds another aspect to the discussion
about complete electrode insertion in cochlear implanta-
tion. We interpret this result as further evidence for the
usefulness of apical cochlear stimulation. The data fromBioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
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objective measurements presented here complement data
from behavioural assessment which show that speech dis-
crimination improves when the most apical region of the
cochlear is stimulated along with the medial and basal
region [27,12]. Restricting the most apical stimulation to
300° to 400° insertion angle does not take advantage of
this portion of the cochlea.
Conclusions
Four different properties of the ECAP in adult subjects
were analysed based on the region of the cochlea where
the response was generated. All four properties analysed
were found to be affected by the cochlear region. Apical
recordings showed on average higher ECAP amplitudes,
lower ECAP thresholds, and steeper slopes of the ECAP
amplitude growth function. Also the ECAP refractory time
showed a significant effect of stimulation region. These
regional differences could be due to the closer proximity
of the stimulating electrode to neural tissue in the apex
and/or to a higher density or survival rate of neural tissue
in the apex, which could also explain the robustness of the
apical response and the steeper growth function. The
recovery inter-pulse interval showed an overall depend-
ence on cochlear region while significant effects between
the individual regions could not be shown.
The novel available large number of ECAP measurements
from the most apical region of the cochlea show that sig-
nificant differences exist between the apical and the basal
region. The apical ECAP recordings show a clear response
with higher (on average) amplitudes and a lower thresh-
old both of which are advantageous in terms of measure-
ment success. These findings imply that future studies
being conducted on ECAPs should include, wherever pos-
sible, a regional analysis of the results to incorporate any
region dependent effects.
Competing interests
The study was sponsored by MED-EL GmbH.
Authors' contributions
SB, JM, RH, AM, S-JB, TS, SH, MD, JM, TZ carried out the
clinical trials. CZ was responsible for the ECAP-signal
processing concept and for the system implementation.
PN and IA conceived the study, undertook its design and
helped to draft the manuscript. SS performed further sta-
tistical analyses and wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
The authors would like to thank the following persons who contributed to 
the study by providing study subjects or assisting in the process: Mr. Stein-
hoff from the Klinikum rechts der Isar of the TU München; Dr. Suckfull 
from the Klinikum Großhadern; Prof. Dr. Gstöttner from the Klinikum JW. 
Goethe-Universität; PD Dr. Mürbe from the Universitätsklinikum Carl 
Gustav Carus; Prof. Dr. Esser from the HELIOS Klinikum Erfurt GmbH; Dr. 
Wesarg from the Universitätsklinik Freiburg; Dr. Maier from the Univer-
sitätsklinikum Hamburg-Eppendorf; Dr. Büchner from the Medizinische 
Hochschule Hannover; Dr Schelhoru-Neide from the Universitätsklinikum 
Jena; Prof. Dr. von Specht from the Otto-von-Guericke-Universität Magde-
burg; Prof. Dr. Pau from the Universtität Rostock; Prof. Dr. Zenner and Dr. 
Tropitisch from the Universitäts-HNO-Klinik Tübingen; Mr. Leiacker from 
the Universitätsklinikum Ulm. We further thank Melissa Waller for here 
comments on the paper, Philipp Spitzer who analyzed the recovery 
sequences, Martina Deibl who performed the initial statistical analysis and 
Robin Cooley who provided medical writing services on behalf of the MED-
EL GmbH.
References
1. Brown CJ, Abbas PJ, Gantz BJ: Preliminary experience with neu-
ral response telemetry in the nucleus CI24 M cochlear
implant.  Am J Otol 1998, 19(3):320-327.
2. Brown CJ, Hughes ML, Luk B, Abbas PJ, Wolaver A, Gervais J: The
relationship between EAP and EABR thresholds and levels
used to program the nucleus 24 speech processor: data from
adults.  Ear Hear 2000, 21(2):151-163.
3. Franck KH: A model of a nucleus 24 cochlear implant fitting
protocol based on the electrically evoked whole nerve action
potential.  Ear Hear 2002, 23(1 Suppl):67S-71S.
4. Franck KH, Norton SJ: Estimation of psychophysical levels using
the electrically evoked compound action potential meas-
ured with the neural response telemetry capabilities of
Cochlear Corporation's CI24 M device.  Ear Hear 2001,
22(4):289-299.
5. Hughes ML, Vander Werff KR, Brown C, Abbas P, Kelsay D, Teagle
H, Lowder MW: A longitudinal study of electrode impedance,
the electrically evoked compound action potential, and
behavioral measures in nucleus 24 cochlear implant users.
Ear & Hearing 2001, 22:471-486.
6. Hochmair-Desoyer I, Schulz E, Moser L, Schmidt M: The HSM sen-
tence test as a tool for evaluating the speech understanding
in noise of cochlear implant users.  Am J Otol 1997, 18(6
Suppl):S83.
7. Zimmerling M, Hochmair ES: EAP recordings in ineraid patients
- correlations with psychophysical measures and possible
implications for patient fitting.  Ear & Hearing 2002, 23:81-91.
8. Abbas PJ, Hughes ML, Brown CJ, Miller CA: Channel interaction in
cochlear implant users evaluated using the electrically
evoked compound action potential.  Audiology & Neuro-Otology
2004, 9(4):203-213.
9. Cohen LT, Richardson LM, Saunders E, Cowan RSC: Spatial spread
of neural excitation in cochlear implant recipients: compari-
son of improved ECAP method and psychophysical forward
masking.  Hearing Research 2003, 179:72-87.
10. Cohen LT, Saunders E, Richardson LM: Spatial spread of neural
excitation: comparison of compound action potential and
forward-masking data in cochlear implant recipients.  Int J
Audiol 2004, 43(6):346-355.
11. Zierhofer CM: Multichannel cochlear implant with neural
response telemetry.  US Patent 2003.
12. Hochmair I, Arnold W, Nopp P, Jolly C, Müller J, Roland P: Deep
electrode insertion in cochlear implants: apical morphology,
electrodes and speech perception results.  Acta Otolaryngol
2003, 123(5):612-617.
13. Polak M, Hodges A, King J, Balkany T: Further prospective find-
ings with compound action potentials from Nucleus 24 coch-
lear implants.  Hearing Research 2004, 188:104-116.
14. Frijns JHM, Briaire JJ, de Laat JA, Grote JJ: Initial evaluation of the
Clarion CII cochlear implant: speech perception and neural
response imaging.  Ear & Hearing 2002, 23:184-197.
15. Anderson I, Deibl M: FS1 Clinical investigation
CRD2005CIP001: experienced users final report.  2007.
16. Anderson I, Deibl M: FS1 Clinical investigation
CRD2005CIP001: inexperienced users final report.  2007.
17. Marques de Sá J: Applied statistics: Using SPSS, STATISTICA, MATLAB and
R 2nd edition. Berlin: Springer; 2007. 
18. Mauchly J: Significance test for sphericity of a normal n-variate
distribution.  Annals of Mathematical Statistics 1940, 11:204-209.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BioMedical Engineering OnLine 2009, 8:40 http://www.biomedical-engineering-online.com/content/8/1/40
Page 10 of 10
(page number not for citation purposes)
19. Greenhouse S, Geisser S: On methods in the analysis of profile
data.  Psychometrika 1959, 24(2):95-112.
20. Bortz J: Statistik für Human- und Sozialwissenschaftler Berlin: Springer;
2005. 
21. Morsnowski A, Charasse B, Collet L, Killian M, Müller-Deile J: Meas-
uring the refractoriness of the electrically stimulated audi-
tory nerve.  Audiol Neurootol 2006, 11(6):389-402.
22. Adamson CL, Reid MA, Mo ZL, Bowne-English J, Davis RL: Firing
features and potassium channel content of murine spiral
ganglion neurons vary with cochlear location.  J Comp Neurol
2002, 447(4):331-350.
23. Reid MA, Flores-Otero J, Davis RL: Firing patterns of type II spi-
ral ganglion neurons in vitro.  J Neurosci 2004, 24(3):733-742.
24. Glueckert R, Pfaller K, Kinnefors A, Rask-Andersen H, Schrott-
Fischer A: The Human Spiral Ganglion: New insights into
ultrastructure, survival rate and implications for cochlear
implants.  Audiology & Neuro-Otology 2005, 10:258-273.
25. Glueckert R, Pfaller K, Kinnefors A, Schrott-Fischer A, Rask-
Andersen H: High resolution scanning electron microscopy of
the human organ of Corti. A study using freshly fixed surgical
specimens.  Hearing Research 2005, 199(1-2):40-56.
26. Lai WK, Dillier N: A Simple Two-Component Model of the
Electrically Evoked Compound Action Potential in the
Human Cochlea.  Audiology & Neuro-Otology 2000, 5:333-345.
27. Hamzavi J, Arnoldner C: Effect of deep insertion of the cochlear
implant electrode array on pitch estimation and speech per-
ception.  Acta Otolaryngol 2006, 126(11):1182-1187.